### PATENT COOPERATION TREATY

From the: INTERNATIONAL SEARCHING AUTHORITY					
То:		PCT			
WRAY & ASSOCIATES Level 4 The Quadrant 1 William Street PERTH WA 6000		WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY			
		(PCT Rule 43bis.1)			
		Date of mailing (day/month/year) 2 6 APR 2005			
Applicant's or agent's file reference		FOR FURTHER ACTION See paragraph 2 below			
114012:MPO:kf International application No. International fil	ling date	(day/month/year) Priority date (day/month/year)			
International approximation		16 February 2004			
International Patent Classification (IPC) or both national cl	lassifica	ation and IPC			
t. Cl. 7 A61K 33/34; A61P 15/16	LTD et al				
Applicant	pplicant				
CONVE LTD et al					
Box No. II Priority  Box No. III Non-establishment of opinion with I Box No. IV Lack of unity of invention  Box No. IV Lack of unity of invention  Reasoned statement under Rule 43b citations and explanations supportin  Box No. VI Certain documents cited  Box No. VII Certain defects in the international at Box No. VIII Certain observations on the international Preliminary Examining Authority ("IPEA") except that the bethe IPEA and the chosen IPEA has notified the International Searching Authority will not be so considered. If this opinion is, as provided above, considered to be a warritten reply together, where appropriate, with amendme PCT/ISA/220 or before the expiration of 22 months from For further options, see Form PCT/ISA/220.	Box No. II Priority  Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability  Box No. IV Lack of unity of invention  Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement  Box No. VI Certain documents cited  Box No. VII Certain defects in the international application  Box No. VIII Certain observations on the international application  RTHER ACTION  a demand for international preliminary examination is made, this opinion will be considered to be a written opinion of the International eliminary Examining Authority ("IPEA") except that this does not apply where the applicant chooses an Authority other than this one to the IPEA and the chosen IPEA has notified the International Bureau under Rule 66.1bis(b) that written opinions of this International arching Authority will not be so considered.  this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a ditten reply together, where appropriate, with amendments, before the expiration of 3 months from the date of mailing of Form CT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later.				
3. For further details, see notes to Form PCT/ISA/220.					
DY THE SELECTION OF THE	International filing date (day/month/year)   Priority date (day/month/year)   16 February 2005   16 February 2004				
Name and mailing address of the IPEA/AU AUSTRALIAN PATENT OFFICE		Authorized Officer			
PO BOX 200, WODEN ACT 2606, AUSTRALIA	200, WODEN ACT 2606, AUSTRALIA S. CHEW				
E-mail address: pct@ipaustralia.gov.au Facsimile No. (02) 6285 3929	Telephone No. (02) 6283 2248				

# WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

International application No.

PCT/AU2005/000197

Box	No. I	Basis of the opinion							
1.	With regar which it w	ard to the language, this opinion has been established on the basis of the international application in the was filed, unless otherwise indicated under this item.	e language in						
	the fo	s opinion has been established on the basis of a translation from the original language into following language , which is the language of a translation furnished for the purposes rnational search (under Rules 12.3 and 23.1(b)).	of						
2.	2. With regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed invention, this opinion has been established on the basis of:								
	a. type of	of material							
		a sequence listing							
	. 🗀	table(s) related to the sequence listing	•						
-	b. format	at of material							
		in written format							
		in computer readable form							
	c. time of	of filing/furnishing							
		contained in the international application as filed.							
		filed together with the international application in computer readable form.							
		furnished subsequently to this Authority for the purposes of search.							
3.	filed	ddition, in the case that more than one version or copy of a sequence listing and/or table relating theretod or furnished, the required statements that the information in the subsequent or additional copies is ide the application as filed or does not go beyond the application as filed, as appropriate, were furnished.	o has been ntical to that						
4.	Additional	al comments:	-						
<b>-</b> ·									
٠.									
			•						
			·						

## WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

International application No.

PCT/AU2005/000197

Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement  1. Statement				
		Claims 9-26	NO	
Inventive	e step (IS)	Claims 1-8, 27	YES	
		Claims 9-26	NO	
Industria	l applicability (IA)	Claims 1-27	YES	
		Claims	NO	
		<del></del>		

#### Citations and explanations:

This report has considered the following documents cited in the International Search Report:

- D1 WO 2003/088983
- D2 WO 1999/027942
- D3 WO 1993/007754

#### NOVELTY (N): Claims 9-26

Claims 9-21 are directed to a contraceptive formulation comprising copper silicate and a pharmaceutically acceptable carrier. Claims 22-26 are directed to a contraceptive device comprising an effective amount of copper silicate. It is considered that the term "contraceptive" is non-limiting and merely denotes that the formulation and device are suitable for contraception.

D1 has disclosed a formulation comprising copper silicate as an acidified aqueous solution or micronised solid. It further discloses a dispensing means comprising a barrier material such as patches, gauzes and bandages impregnated with copper silicate (see page 2 lines 14-23, page 4 lines 18-20, page 8 lines 1-14 and the claims).

Therefore claims 9-26 lack novelty in view of the disclosures of D1.

D2 has disclosed a formulation comprising copper silicate in liquid or solid form (see page 3 lines 1-21).

D3 has disclosed a formulation comprising an aqueous acidified solution of copper silicate (see abstract).

Therefore claims 9-21 lack novelty in view of the disclosures of each of D2 and D3.

#### **INVENTIVE STEP (IS): Claims 9-26**

As above.

#### INDUSTRIAL APPLICABILITY (IA): Claims 1-27

Claims 1-27 have industrial applicability.